cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2014-2-71-75cardiovascular-46Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMРОЛЬ ГЕНЕТИЧЕСКОГО ТЕСТИРОВАНИЯ В ПОДБОРЕ ОПТИМАЛЬНОЙ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ В ЛЕЧЕНИИ БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦАТHE ROLE OF GENETIC TESTING FOR OPTIMAL ANTIPLATELET THERAPY SELECTION IN THE TREATMENT OF CORONARY ARTERY DISEASE PATIENTSМацкеплишвилиС. Т.MatskeplishviliS. T.

д. м.н., главный научный сотрудник клинико-диагностического отделения

iko83@mail.ruАрутюноваЯ. Э.ArutyunovaY. E.

аспирант отделения

iko83@mail.ruНаучный центр сердечно-сосудистой хирургии им. А. Н. Бакулева РАМН, МоскваBakulev scientific center for cardiovascular surgery. Moscow, Russia2014200420141327175Copyright © Мацкеплишвили С.Т., Арутюнова Я.Э., 20142014Мацкеплишвили С.Т., Арутюнова Я.Э.Matskeplishvili S.T., Arutyunova Y.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/46

Изучение ишемической болезни сердца (ИБС), как причины снижения качества жизни и утраты трудоспособности населения, обусловили совершенствование методов диагностики и лечения этой патологии. В настоящее время накопилась большая доказательная база в пользу применения двойной антитромбоцитарной терапии у пациентов с ИБС после проведенного коронарного стентирования. По данным тех же исследований у части пациентов все же наблюдаются случаи развития такого грозного осложнения, как тромбоз стента. В связи с этим в последнее время все шире стал изучаться вопрос о роли генетического тестирования в подборе оптимальной антитромбоцитарной терапии в лечении больных ИБС.

The studies of coronary heart disease as a cause of reduced life quality and disability in population led to improved methods of diagnosis and treatment of this disease. To date, accumulated large evidence base supports the use of DAT (dual antiplatelet therapy) in patients with coronary artery disease after PCI. According to the same data some patients still develop severe complications, i. e. stent thrombosis. In this regard, recent years there is increasing importance of the genetic testing for selection of the optimal antiplatelet therapy in patients with coronary artery disease.

ишемическая болезнь сердцадвойная антитромбоцитарная терапиягенетическое тестированиеcoronary artery diseasedual antiplatelet therapygenetic testingReferencesKomarov A. L. Recommendations for antitrombotic therapy for percutaneous coronary intervention. Atherothrombosis 2010; 1: 87–95. Russian (Комаров А. Л. Рекомендации по антитромботической терапии при чрескожных вмешательствах на коронарных артериях. Атеротромбоз 2010; 1: 87–95).Komarov A. L. Recommendations for antitrombotic therapy for percutaneous coronary intervention. Atherothrombosis 2010; 1: 87–95. Russian (Комаров А. Л. Рекомендации по антитромботической терапии при чрескожных вмешательствах на коронарных артериях. Атеротромбоз 2010; 1: 87–95).Mehta SR, Salim Y, Peters RSG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI–CURE study. The Lancet 2001; 358: 527–33.Mehta SR, Salim Y, Peters RSG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI–CURE study. The Lancet 2001; 358: 527–33.Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 2005; 352: 1179–89.Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 2005; 352: 1179–89.Steinhubl SR, Berger PB, Brennan DM, et al. Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention. JACC 2006; 47: 939–43).Steinhubl SR, Berger PB, Brennan DM, et al. Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention. JACC 2006; 47: 939–43).Bhatt DL, Fox KAA, et al. Clopidogrel and Aspirin versus Aspirin A lone fore the Prevention of Atherothrombotic Events. N Engl J Med 2006; 354: 1706–17.Bhatt DL, Fox KAA, et al. Clopidogrel and Aspirin versus Aspirin A lone fore the Prevention of Atherothrombotic Events. N Engl J Med 2006; 354: 1706–17.Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events afterclopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. JACC 2006; 48: 2584–91.Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events afterclopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. JACC 2006; 48: 2584–91.Pavlova TV, Dupliakov DV. Outstanding issues clopidpgrel with acute ischemic heart disease. Effective drug treatment in cardiology and angiology 2010; 2: 44–9. Russian (Павлова Т. В., Дупляков Д. В. Нерешенные вопросы применения клопидогрела при обострении ишемической болезни сердца. Эффективная фармакотерапия в кардиологии и ангиологии 2010; 2: 44–9).Pavlova TV, Dupliakov DV. Outstanding issues clopidpgrel with acute ischemic heart disease. Effective drug treatment in cardiology and angiology 2010; 2: 44–9. Russian (Павлова Т. В., Дупляков Д. В. Нерешенные вопросы применения клопидогрела при обострении ишемической болезни сердца. Эффективная фармакотерапия в кардиологии и ангиологии 2010; 2: 44–9).Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450–1A. Thromb Haemost 1994; 72 (2): 313–7.Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450–1A. Thromb Haemost 1994; 72 (2): 313–7.Sumarokov AB, Burachkovskaya LB. The use of thienopyridines in patients with atherosclerotic lesions of the arteries. Guide for Physicians. Moscow 2012; 6–10. Russian (Сумароков А. Б., Л. Б. Бурячковская. Применение тиенопиридинов в лечении больных с атеросклеротическим поражением артерий. Руководство для врачей. Москва 2012; 6–10).Sumarokov AB, Burachkovskaya LB. The use of thienopyridines in patients with atherosclerotic lesions of the arteries. Guide for Physicians. Moscow 2012; 6–10. Russian (Сумароков А. Б., Л. Б. Бурячковская. Применение тиенопиридинов в лечении больных с атеросклеротическим поражением артерий. Руководство для врачей. Москва 2012; 6–10).Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidpgrel responsiveness in healthy subjects. Blood 2008; 108: 2244–7.Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidpgrel responsiveness in healthy subjects. Blood 2008; 108: 2244–7.Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429–36.Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429–36.Young-Hoon Jeong, MD, PHD,* In-Suk Kim, MD, PHD,† Yongwhi Park, MD, PHD,* et al. Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day Results of the ACCEL-DOUBLE. JACC 2010; 3 (7): 731–41.Young-Hoon Jeong, MD, PHD,* In-Suk Kim, MD, PHD,† Yongwhi Park, MD, PHD,* et al. Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day Results of the ACCEL-DOUBLE. JACC 2010; 3 (7): 731–41.Collet JP, Hulot JS, Anzaha G; High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACС 2011; 4: 392–402.Collet JP, Hulot JS, Anzaha G; High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACС 2011; 4: 392–402.Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 2011; 75 (1): 99–105.Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 2011; 75 (1): 99–105.Graciansky HA. Antiplatelet therapy for coronary heart disease. Some of the challenges and achievements. Atherothrombosis 2010; 1 (4): 2–52. Russian (Грац ианский Н. А. Антитромбоцитарная терапия при коронарной болезни сердца. Некоторые проблемы и достижения. Атеротромбоз 2010; 1 (4): 2–52).Graciansky HA. Antiplatelet therapy for coronary heart disease. Some of the challenges and achievements. Atherothrombosis 2010; 1 (4): 2–52. Russian (Грац ианский Н. А. Антитромбоцитарная терапия при коронарной болезни сердца. Некоторые проблемы и достижения. Атеротромбоз 2010; 1 (4): 2–52).Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients UF/NSTEMI (updating the 2007 guideline and replacing the 2011 focused update): a report of the AACF/AHA Task Force on Practice Guidelines. Circulation 2012; 126: 875–910.Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients UF/NSTEMI (updating the 2007 guideline and replacing the 2011 focused update): a report of the AACF/AHA Task Force on Practice Guidelines. Circulation 2012; 126: 875–910.Wiviott SD, Braunwald E. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001–15.Wiviott SD, Braunwald E. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001–15.Yavelov IS. On the approach to the selection of antiplatelet agents for dual antiplatelet therapy for acute coronary syndrome. Clinical Pharmacology and Therapeutics 2012; 21 (3): 46–53. Russian (Явелов И. С. О подходах к выбору антиагрегантов для двойной антитромбоцитарной терапии острого коронарного синдрома. Клиническая фармакология и терапия 2012; 21 (3): 46–53).Yavelov IS. On the approach to the selection of antiplatelet agents for dual antiplatelet therapy for acute coronary syndrome. Clinical Pharmacology and Therapeutics 2012; 21 (3): 46–53. Russian (Явелов И. С. О подходах к выбору антиагрегантов для двойной антитромбоцитарной терапии острого коронарного синдрома. Клиническая фармакология и терапия 2012; 21 (3): 46–53).Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131–41.Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131–41.

The authors declare that there are no conflicts of interest present.